Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-12

Clinical Trial Update: A Trial of AXS-05 in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial results for AXS-05 in major depressive disorder have been completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Depression, Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2022-10-12